Introduction {#sec001}
============

Ebolaviruses are negative-sense single-stranded RNA (ssRNA) viruses capable of causing acute haemorrhagic fever. The prototypical Ebola virus (EBOV; *Zaire ebolavirus*) was responsible for the recent West Africa outbreak that resulted in 28,000 cases and 11,000 deaths between 2014 and 2016 \[[@pntd.0006349.ref001]\]. The reservoir of this lethal pathogen has not been conclusively proven, though there is good evidence suggesting fruit bats as a primary source of exposure \[[@pntd.0006349.ref002]\]. Furthermore, survivors of ebolavirus disease (EVD) can carry the virus in immunologically privileged sites for over one year, post-recovery from the acute infection \[[@pntd.0006349.ref003],[@pntd.0006349.ref004]\]. Resultantly, there is an increased awareness of the risk of alternate forms of transmission in EVD as survivors may carry EBOV in semen for over 12 months, causing sexual transmission, or in breast milk, which can lead to infection of newborns \[[@pntd.0006349.ref004],[@pntd.0006349.ref005]\]. In 2004, funding from Project BioShield (United States Department of Health and Human Services) spurred research that has led to the development of novel therapeutics to prevent and treat EVD, resulting in a very promising vaccine that was evaluated during the 2014 outbreak and showed 100% efficacy in disease prevention \[[@pntd.0006349.ref006],[@pntd.0006349.ref007]\]. Following Project BioShield and the 2014 West Africa outbreak, there has been extensive research into the ebolaviruses that has greatly expanded our understanding of viral replication and pathogenesis.

*Ebolavirus* is a genus within the family Filoviridae, which also includes the genus *Marburgvirus* (e.g., Marburg virus: MARV) and *Cuevavirus* (e.g., Lloviu virus) \[[@pntd.0006349.ref008]\]. The *Ebolavirus* genus contains five species: *Zaire ebolavirus*, *Sudan ebolavirus*, *Taï Forest ebolavirus*, *Bundibugyo ebolavirus*, and lastly, *Reston ebolavirus*, the only member that is nonpathogenic in humans for reasons that are still unclear \[[@pntd.0006349.ref009]\]. The majority of research has focused on *Zaire ebolavirus*, as this species has been associated with the greatest number of outbreaks and has the highest case--fatality rates of all the ebolaviruses (30%--90%, depending on the specific outbreak), though as a consequence, many novel or species-specific functions of ebolavirus proteins may be undiscovered. The 19 kb viral genome encodes for seven main proteins: nucleoprotein (NP), glycoprotein (GP), L-polymerase (L) protein, viral protein (VP) 24, VP30, VP35, and VP40 ([Fig 1](#pntd.0006349.g001){ref-type="fig"}) \[[@pntd.0006349.ref010]\]. L is an RNA-dependent RNA polymerase (RdRp) and forms the RdRp complex with VP30 that is responsible for viral genome transcription and replication. VP24 and VP35 inhibit interferon (IFN) signalling and facilitate evasion of the host immune response. NP encapsidates the viral genome into the nucleocapsid, whilst VP40 drives viral assembly and budding. GP is the only protein on the surface of the virion and is essential for binding to target cells and subsequently mediating membrane fusion and the release of the viral genome. However, recent research has uncovered a multitude of new, often overlapping roles for ebolavirus proteins, and it is not possible to view viral replication as a one-protein--one-function process ([Table 1](#pntd.0006349.t001){ref-type="table"}). In this review, we examine the collection of recently identified secondary functions of ebolavirus proteins in order to provide a more comprehensive understanding of roles of each protein in viral replication and pathogenicity.

![Genome organisation of Filoviridae family members: MARV, EBOV, and RESTV.\
Each box represents the open-reading frames that produce the VPs. RNA editing by addition of Us occurs on the GP transcript in order to produce GP and the ssGP. Post-translational modification of the GP protein results in two GP subunits after cleavage by host furin. Slight differences in gene overlaps and the presence of intergenic regions are evident between the different ebolavirus species, though the functional consequence of these differences is not clear at present. EBOV, Ebola virus; GP, glycoprotein; L, L-polymerase; MARV, Marburg virus; NP, nucleoprotein; RESTV, Reston virus; sGP; soluble glycoprotein; ssGP, small soluble glycoprotein; U, uridine; VP, viral protein.](pntd.0006349.g001){#pntd.0006349.g001}

10.1371/journal.pntd.0006349.t001

###### Summary of ebolavirus protein roles.

![](pntd.0006349.t001){#pntd.0006349.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein   Main Role                                                                                                                            Secondary Role
  --------- ------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------
  VP24      Inhibits IFN-α/β and IFN-γ signalling through interactions with importins, STAT signalling pathways, and NF-κB signalling pathways   Nucleocapsid assembly and stability\
                                                                                                                                                 RNA incorporation into VLPs\
                                                                                                                                                 Regulates transcription and translation

  VP30      Initiates ebolavirus transcription                                                                                                   Counters RNA interference

  VP35      Inhibits type-I IFN signalling by inhibiting activation of IRF-3 via dsRNA binding\                                                  Assembly of viral complex with NP and VP30\
            Inhibits type-I IFN production by upregulating SUMOylation of IRF-7\                                                                 Regulates RNA synthesis by modulating NP--RNA interactions and by interacting with dynein LC8
            Impairs dendritic cell maturation\                                                                                                   
            Counters RNA interference\                                                                                                           
            Inhibits antiviral effects by blocking protein kinase R                                                                              

  VP40      Viral assembly and budding                                                                                                           Counters RNA interference\
                                                                                                                                                 Induces apoptosis in bystander lymphocytes

  GP        Virus attachment and entry                                                                                                           Late-stage cytotoxicity in cells\
                                                                                                                                                 Decreases endothelial barrier function\
                                                                                                                                                 Directly triggers T-lymphocyte death and augments monocyte maturation

  NP        Key component of ribonucleoprotein complex, encapsidates viral genome and protects viral mRNA from degradation                       

  L         Involved in transcription and regulation of viral genome and mRNA editing                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** dsRNA, double-stranded RNA; GP, glycoprotein; IFN, interferon; IRF, interferon regulatory factor; L, L-polymerase; LC8, light chain 8; NF-κB, nuclear factor kappa B; NP, nucleoprotein; STAT, signal transducer and activator of transcription; SUMO, small ubiquitin-like modifier; VLPs, virus-like particles; VP, viral protein

VP24 {#sec002}
====

VP24 is one of the most studied filovirus proteins, with the majority of studies focusing on its primary role in inhibiting the host IFN response. VP24 is known to inhibit IFN-α/β and IFN-γ activation by binding to key host proteins from the karyopherin α family (karyopherin α1, α5, and α6) preventing their binding to and the subsequent nuclear import of signal transducer and activator of transcription 1 (STAT1) \[[@pntd.0006349.ref011]\]. In addition, VP24 blocks IFN signalling by directly binding to STAT1, preventing its phosphorylation, nuclear import, and transcription of IFN-stimulated genes (ISG) \[[@pntd.0006349.ref011]--[@pntd.0006349.ref013]\]. Recent data suggest VP24 is also able to block IFN induction by supressing nuclear factor-kappa B (NF-kB) activation following tumour necrosis factor alpha (TNF-α) stimulation \[[@pntd.0006349.ref014]\] and by supressing retinoic acid-inducible gene I (RIG-I)--dependent activation of IFN-γ1 gene expression \[[@pntd.0006349.ref015]\]. Furthermore, the innate response antagonist domains (IRAD) in EBOV VP24 and VP35 have been implicated in preventing the maturation of EBOV-infected dendritic cells by modulating global gene expression \[[@pntd.0006349.ref016],[@pntd.0006349.ref017]\]. This effect required both VP24 and VP35 IRAD domains, though the VP24 IRAD domain alone was sufficient to down-regulate cytokine signalling pathways \[[@pntd.0006349.ref017]\]. These results highlight the importance of cooperative action of multiple viral proteins for evasion of the host immune response.

VP24 has also recently been seen to function in capsid assembly \[[@pntd.0006349.ref018]\]. NP and VP35 are known to be the major components of the viral nucleocapsid, though VP24 is weakly associated and may act as a catalyst for particle formation \[[@pntd.0006349.ref018]\]. Further evidence for a structural role of VP24 comes from the observation that N- or C-terminal deletions in VP24 inhibited the formation of nucleocapsid-like structures mediated by VP24, VP35, and NP coexpression \[[@pntd.0006349.ref019]\]. It was suggested that the N-terminal domain of VP24 facilitates capsid formation by mediating protein--protein interactions. This is supported by the observation that mutation of the VP24 N-terminal domain results in protein aggregation \[[@pntd.0006349.ref019]\]. A recent study confirmed the interaction between VP24 and NP, showing that VP24 residues V170 and N171 are located on a highly conserved exposed loop that interacts with NP during nucleocapsid assembly \[[@pntd.0006349.ref020]\]. Coexpression of VP24 and VP40 results in a greater production of virus-like particles (VLPs) than when VP40 is expressed alone \[[@pntd.0006349.ref021]\]. Similarly, in live EBOV infection, VP24 small interfering RNA (siRNA) knockdown decreases viral budding and increases the retention of viral proteins within the cell \[[@pntd.0006349.ref022]\]. Further evidence suggests that VP24 binds to VP35 on the outer surface of the nucleocapsid where it organises the adjacent NP layer, promoting nucleocapsid stability and explaining the observed interactions between NP, VP24, and VP35 during nucleocapsid formation \[[@pntd.0006349.ref023]\].

In addition to its role in nucleocapsid stability, VP24 may be necessary for incorporation of the viral RNA (vRNA) genome into the nucleocapsid. Several studies have shown that VP24, together with VP35, induce conformational changes in NP that are necessary for RNA encapsidation \[[@pntd.0006349.ref018],[@pntd.0006349.ref024],[@pntd.0006349.ref025]\]. It was shown that VP24 may be directly involved in length-dependent vRNA interactions and packaging \[[@pntd.0006349.ref026]\]. In the study, transcription- and replication-competent virus-like particles (trVLPs) were analysed for RNA content, and a significant reduction of packaged RNA was observed when VP24 was knocked down with an interfering micro-RNA (miRNA). The trVLPs that were produced showed a 2-fold reduction in RNA content and a 10-fold reduction of infectivity, suggesting that VP24 may play an essential role in RNA packaging. Furthermore, disruption of the VP24--NP interaction reduced RNA packaging and resulted in a significant reduction in reporter activity, highlighting the importance of VP24 in RNA packaging \[[@pntd.0006349.ref020]\]. In addition, trVLP reporter gene activity was significantly affected by the presence of VP24 in a genome-length-dependent manner. Using the trVLP tetracistronic genome system, the presence of VP24 during VLP production resulted in a 25-fold increase in reporter gene activity upon subsequent infection, whereas the presence of VP24 had no effect when monocistronic minigenome systems were used in the trVLP, suggesting a genome-length-dependent role for VP24 in RNA packaging and VLP infectivity. Surprisingly, VP24 may also have a length-dependent role in transcriptional regulation. It was observed that VP24 moderately inhibited the expression of reported genes from monocistronic minigenome plasmids \[[@pntd.0006349.ref027]\]. However, VP24 expression had no effect on protein expression from the trVLP tetracistronic genomes \[[@pntd.0006349.ref026]\]. Whilst the impact of VP24 on protein expression is not clear, VP24 itself may be subject to length-dependent transcriptional regulation. Recent work has implicated the length of the intergenic region (IR) between VP30 and VP24 as having a significant impact on VP24 expression by regulating transcription initiation frequency ([Fig 1](#pntd.0006349.g001){ref-type="fig"}) \[[@pntd.0006349.ref028],[@pntd.0006349.ref029]\]. The importance of the broad range of VP24 functions during virus replication is highlighted by the fact that it has not been possible to create a VP24-deficient recombinant EBOV, even when VP24 is supplied in *trans* \[[@pntd.0006349.ref022]\].

VP35 {#sec003}
====

As with VP24, VP35 is primarily known for its multifaceted ability to suppress the host cell immune response. VP35 is a type-I IFN antagonist, inhibiting the activation of interferon regulatory factor (IRF)-3 via double-stranded RNA (dsRNA) binding and reducing IFN-α/β production by inhibiting RIG-I signalling \[[@pntd.0006349.ref030]--[@pntd.0006349.ref032]\]. VP35 also blocks IFN production by increasing protein inhibitor of activated STAT1 (PIAS1)-mediated SUMOylation of IRF-7, thus inhibiting IFN production following toll-like receptor (TLR) and RIG-I activation \[[@pntd.0006349.ref033]\]. Lastly, VP35 is a suppressor of RNA silencing, functionally equivalent to the human immunodeficiency virus (HIV-1) *Trans*-activator of transcription (Tat) protein and important for viral evasion of the innate immune response \[[@pntd.0006349.ref034]\]. Together, there is significant evidence demonstrating VP35's intricate ability to inhibit innate immune signalling and the host antiviral response ([Fig 2](#pntd.0006349.g002){ref-type="fig"}).

![Multiple roles of VP35 during virus replication.\
VP35 inhibits the type-I IFN response through several different mechanisms. VP35 can bind to dsRNA, preventing the activation of RIG-I signalling. In addition, VP35 blockade of IRF3 and IRF7 phosphorylation inhibits the production of IFN-β. Recent studies have also highlighted the importance of VP35 in regulating NP--RNA association. During viral genome replication, the VP35 N-terminal peptide binds to NP, enabling the vRNA to associate with the RdRp complex for replication. During virus assembly, VP35 disassociates, enabling NP to oligomerise, bind RNA, and form the nucleocapsid. 5'PPP, 5' triphosphate; dsRNA, double-stranded RNA; IFN, interferon; IKK, inhibitor of nuclear factor kappa B kinase subunit epsilon; IRF, interferon regulatory factor; MAVS, mitochondrial antiviral-signalling protein; MDA5, melanoma differentiation-associated protein 5; NP, nucleoprotein; PACT, protein activator of the interferon-induced protein kinase; RdRp, RNA-dependent RNA polymerase; RIG-I, retinoic acid-inducible gene I; TANK, tumour necrosis factor--receptor-associated factor family member--associated nuclear factor kappa B activator; TBK1, tumour necrosis factor--receptor-associated factor family member--associated nuclear factor kappa B activator binding kinase 1; TRAF3, tumour necrosis factor--receptor-associated factor 3; VP, viral protein; vRNA, viral RNA.](pntd.0006349.g002){#pntd.0006349.g002}

Recent work suggests that VP35 may have more diverse functions during virus replication, as VP35 was shown to interact with L and facilitate genome transcription through the formation of the RdRp complex and genome packaging through association with NP \[[@pntd.0006349.ref035]--[@pntd.0006349.ref037]\]. The first 450 residues of VP35 appear to be essential for binding to L and thus RdRp function, whereas the C-terminus associates with NP, thus linking NP and L during nucleocapsid assembly \[[@pntd.0006349.ref036],[@pntd.0006349.ref038]\]. N-terminal deletions in VP35 block these interactions and were sufficient to inhibit the replication and transcription of an EBOV minigenome system \[[@pntd.0006349.ref038]\]. The role of the VP35 C-terminus in capsid assembly is perhaps surprising, as this region contains the IFN inhibitory domain responsible for its main role in immune evasion. However, this domain contains several conserved stretches of basic residues involved in dsRNA binding and IFN inhibition, whereas a preceding stretch mediates interaction with NP \[[@pntd.0006349.ref036]\]. Further research found the VP35--NP interaction controls the switch between RNA-bound NP and free NP, thus switching between genome replication and genome packaging in the nucleocapsid \[[@pntd.0006349.ref039]\]. An N-terminal peptide derived from the VP35 NP-binding protein region (NPBP) binds NP with high affinity, causing the release of RNA from NP and resulting in the activation of genome transcription and the inhibition of NP oligomerisation ([Fig 2](#pntd.0006349.g002){ref-type="fig"}) \[[@pntd.0006349.ref039]\]. Additional investigation of VP35--NP binding showed two further interaction sites. Hydrophobic VP35--NP binding at these sites inhibited NP oligomerisation and prevented NP--RNA binding by blocking access to the RNA binding domain \[[@pntd.0006349.ref040]\]. Work by Leung and colleagues suggests that during nucleocapsid formation, the NPBP peptide first disassociates from NP, then RNA binds to NP, followed by NP oligomerisation. In contrast, Kirchdoerfer and colleagues show that monomeric NP has no significant affinity for RNA, suggesting that the NPBP peptide would be displaced by an additional NP molecule, causing NP oligomerisation that would then allow for RNA binding. However, in either process, VP35--NP interactions are crucial for virus replication and are being explored as targets for future therapeutics \[[@pntd.0006349.ref041],[@pntd.0006349.ref042]\].

VP35 also undergoes further protein--protein interactions that may affect viral genome transcription through the interaction with the cytoplasmic dynein light chain (LC8) \[[@pntd.0006349.ref043]\]. LC8 is a highly conserved 8 kDa subunit of the cytoplasmic dynein motor complex but can also exist as a dimer in soluble form, which can affect viral transcription and assembly \[[@pntd.0006349.ref044],[@pntd.0006349.ref045]\]. LC8 was seen to stabilise VP35 N-terminal oligomerisation in a dose-dependent manner and enhance viral genome synthesis \[[@pntd.0006349.ref046]\]. It was noted that LC8 functions mostly in the early stages of infection, enhancing early viral gene expression before the host cells are able to establish the antiviral state. Thus, VP35 modulation of vRNA transcription can facilitate virus replication while simultaneously enhancing immune evasion.

VP30 {#sec004}
====

The minor nucleoprotein VP30 has the primary role of initiating EBOV transcription \[[@pntd.0006349.ref047]\]. It is dynamically phosphorylated, whereby upon phosphorylation, transcription is negatively regulated, enabling binding to NP \[[@pntd.0006349.ref048],[@pntd.0006349.ref049]\]. In turn, this permits interactions that regulate vRNA synthesis \[[@pntd.0006349.ref037]\]. VP30 binds zinc ions due to the presence of an unconventional zinc-binding motif, facilitating RNA binding and increasing viral genome transcription \[[@pntd.0006349.ref050]--[@pntd.0006349.ref053]\].

In addition to its RNA-binding role in transcription, VP30 also interferes with cellular RNA silencing \[[@pntd.0006349.ref054]\]. In the presence of siRNA, VP30 was seen to interact with the essential RNA interference (RNAi) protein Dicer, though the VP35 N-terminus RNA binding domain was not required for the interaction or for the suppression of RNAi ([Fig 3](#pntd.0006349.g003){ref-type="fig"}). As with the RNA silencing suppressor activity of VP35, the exact role of RNAi in antiviral immunity is not clear, nor is the consequence on EBOV replication of blocking miRNA/siRNA processing as mediated by VP30 \[[@pntd.0006349.ref055]\]. However, despite the fact that RNA binding is not required for RNA silencing suppression, VP30 was seen to bind to a variety of nonviral RNAs. VP30--RNA binding required specific base composition and structure of the target RNA molecule \[[@pntd.0006349.ref053]\], though it is not clear if there is a function of VP30 binding to nonviral RNA or if this is a consequence of its necessary binding to vRNA during transcription.

![Ebolavirus proteins VP30, VP35, and VP40 are suppressors of RNA silencing.\
Cellular RNA interference requires the assembly of the Dicer:TRBP:PACT complex. VP30 inhibits RNAi by interacting with Dicer, preventing TRBP binding and complex activity. VP35 also inhibits complex assembly by binding TRBP and PACT, preventing their association with Dicer. VP40 suppresses RNAi during infection or when transferred to bystander immune cells through exosomes, though the mechanism by which VP40 inhibits the Dicer machinery is currently unknown. PACT, protein activator of the interferon-induced protein kinase; RNAi, RNA interference; TRBP, *Trans*-activation response RNA binding protein; VP, viral protein.](pntd.0006349.g003){#pntd.0006349.g003}

VP40 {#sec005}
====

The matrix protein VP40 has roles predominantly in virus assembly and budding \[[@pntd.0006349.ref056],[@pntd.0006349.ref057]\]. VP40 can assemble either as a hexamer, which appears to be involved in budding, or as an octamer that functions in genome replication and RNA binding \[[@pntd.0006349.ref058],[@pntd.0006349.ref059]\]. Most research has focused on the role of VP40 in assembly and budding; however, recent studies have begun to elucidate novel roles.

VP40 is known to be sufficient to mediate the formation and budding of VLPs; however, recent results have demonstrated that VP40 induces the formation for exosomes that are capable of inducing bystander cell death \[[@pntd.0006349.ref060],[@pntd.0006349.ref061]\]. Exosome release has been seen in virally infected cells, and VP40 expression was seen to increase the expression of several endosomal sorting complex required for trafficking (ESCRT) proteins involved in exosome biogenesis, including tumour susceptibility gene 101 (TSG101), vacuolar protein-sorting-associated protein 25 (VPS25), and VPS36 \[[@pntd.0006349.ref061],[@pntd.0006349.ref062]\]. This is consistent with previous reports showing VP40 utilising ESCRT proteins to aid viral budding, though how VP40 switches between budding and exosome release is not clear \[[@pntd.0006349.ref063]--[@pntd.0006349.ref065]\].

Transfer of VP40-induced exosomes to naïve T lymphocytes and monocytes induced apoptosis and significantly reduced cell viability similarly to that seen when exosomes from virally infected cells were used \[[@pntd.0006349.ref061],[@pntd.0006349.ref062]\]. However, Pleet and colleagues noted that the presence of VP40 in the exosomes caused a down-regulation of miRNA machinery in both the donor and recipient cells, including a reduction in the expression of Dicer, argonaute-1, and Drosha ([Fig 3](#pntd.0006349.g003){ref-type="fig"}). It was previously noted that VP35, VP30, and VP40 are capable of interacting with the miRNA/RNAi pathway \[[@pntd.0006349.ref054]\]; however, this was the first demonstration that the suppression of RNA silencing can be transferred to naïve cells in the absence of virus. Currently, the precise mechanism in which VP40 interacts with miRNA machinery has yet to be characterised, and it is not yet known if the action of VP40 on the miRNA machinery directly causes apoptosis or if the exosomes contain other proteins or RNAs that may be responsible for causing the induction of apoptosis. However, the repression of key proteins in the miRNA pathway has been previously linked to the induction of apoptosis; thus, the suppression of RNA silencing may serve both to directly counteract the innate cellular immune response and to induce apoptosis of bystander immune cells, blocking the activation of adaptive immunity \[[@pntd.0006349.ref057],[@pntd.0006349.ref061],[@pntd.0006349.ref066]\].

Due to the essential role of VP40 in viral assembly and budding, several studies have looked at inhibiting VP40 for the creation of new antiviral therapeutics \[[@pntd.0006349.ref067],[@pntd.0006349.ref068]\]. As VP40 also plays a role in immune evasion (via RNAi suppression and exosome-bystander cell death), there is increased motivation for developing therapeutics that target one or multiple functions of VP40. It is known that viral replication requires VP40 phosphorylation at tyrosine 13 by the cellular tyrosine kinase Abelson murine leukaemia viral oncogene homologue 1 (c-Abl1) \[[@pntd.0006349.ref069]\]. In addition, recent results showed that cyclin-dependent kinase 2 (Cdk2) in complex with Cyclin A or Cyclin E phosphorylated exosomal VP40 at serine-233 \[[@pntd.0006349.ref061]\]. Thus, the inhibition or modulation of VP40 phosphorylation may be a target for new therapeutics. Lastly, Pleet and colleagues showed that treatment with the FDA-approved drug Oxytetracycline reduced VP40 exosome release and significantly increased donor cell viability upon treatment with VP40 exosomes, further suggesting that targeting the secondary functions of VP40 may be a new approach for developing antivirals for EVD.

GP {#sec006}
==

The GP gene has been shown to encode for three different products due to transcriptional editing by L: full length GP, which consist of GP1 (receptor binding) and GP2 (viral fusion) subunits; soluble GP (sGP), which lacks the transmembrane domain; and small soluble GP (ssGP) \[[@pntd.0006349.ref070],[@pntd.0006349.ref071]\]. Due to furin cleavage of sGP, a smaller cleaved fragment is also produced, called Δ-peptide \[[@pntd.0006349.ref072]\]. GP is the only viral protein located on the surface of the virion and has a critical role in attachment and fusion \[[@pntd.0006349.ref073]--[@pntd.0006349.ref075]\]. Ebolaviruses are thought to predominantly enter cells via GP-dependent macropinocytosis, though other mechanisms have been reported, depending on factors such as host cell type \[[@pntd.0006349.ref076],[@pntd.0006349.ref077]\]. After entry, GP directs fusion between the viral membrane and endolysosomes that contain the viral receptor Niemann-Pick C1 (NPC1) and two-pore segment channel 2 (TPC2), enabling release of the viral genome \[[@pntd.0006349.ref078],[@pntd.0006349.ref079]\]. During the 2014--2016 outbreak, a mutation in GP at A82V was detected with high frequency \[[@pntd.0006349.ref080]--[@pntd.0006349.ref082]\]. This mutation increased GP membrane fusion activity and increased infectivity in a variety of cell types, including chimpanzee fibroblasts (S008842), rhesus epithelial (FRhK4), African green monkey epithelial (Vero), and human dendritic cells. The authors propose that this mutation is likely a result of EBOV adaptation to the human host, as several viral variants have been seen to increase human cell infectivity while decreasing virus entry in nonhuman primates \[[@pntd.0006349.ref083]--[@pntd.0006349.ref085]\]. Thus, the specific nature of protein function needs to be considered in the context of the given host.

GP has been shown to have a multitude of secondary roles beyond attachment and fusion that affect both virus replication and pathogenicity. Several studies have shown that GP contributes to EBOV virulence; however, it is not sufficient on its own to be defined as a virulence marker, despite having marked effects beyond entry and fusion \[[@pntd.0006349.ref086]\]. EBOV GP expression has been well established as having a cytotoxic effect on host cells \[[@pntd.0006349.ref087]--[@pntd.0006349.ref089]\]. GP cytotoxicity is mediated through the mucin-like domain and its effect on the extracellular signal--regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathway \[[@pntd.0006349.ref090]\]. EBOV GP reduces the phosphorylation and catalytic activity of ERK2, resulting in the loss of cell adherence, cell rounding, and the induction of non-apoptotic cell death. The decrease in ERK2 activity was also necessary for GP-induced down-regulation of αV integrin expression, further impairing cell adherence and tight junction formation. In addition, the sGP cleavage product, Δ-peptide, may play a role in EBOV pathogenicity by acting as a viroporin \[[@pntd.0006349.ref091]\]. Δ-peptide is able to form pores in the plasma membrane of mammalian cells, increasing ion permeability and causing cytotoxicity \[[@pntd.0006349.ref092]\]. However, it is not known if the Δ-peptide can be released from cells or if its induction of cytotoxicity is limited to within the infected cell. In order to regulate the toxicity caused by GP and its cleavage products at early stages of infection, GP expression is dynamically regulated \[[@pntd.0006349.ref093]\]. The balance and timing of EBOV GP/sGP/ssGP/shed-GP/Δ-peptide expression has been found to be pivotal in virus replication, affecting not only cell death but viral assembly and budding \[[@pntd.0006349.ref094]\].

Whilst VP40 expression is sufficient to produce VLPs, GP expression enhances VLP generation, suggesting a possible secondary role for GP in viral egress \[[@pntd.0006349.ref021]\]. Recent work suggests that GP does not directly affect viral assembly or budding, but rather counteracts the cellular budding restriction factor tetherin \[[@pntd.0006349.ref095]\]. In the absence of GP, VLPs assemble and bud but are retained on the cell surface through the antiviral tethering actions of the tetherin protein. GP expression enabled VLP release but did not affect tetherin cell-surface localisation, nor was a specific GP--tetherin interaction found \[[@pntd.0006349.ref096]\]. It was shown that the GP glycosylation and its receptor-binding domain (RBD) were critical for anti-tetherin activity, though mutation of the RBD did not affect interactions with tetherin, and inhibition of GP--NPC1 binding did not affect the anti-tetherin activity \[[@pntd.0006349.ref097]\]. Instead, it is thought that GP is specifically able to block the association between VP40 and tetherin, though the nature of tetherin--VP40 interaction and the mechanism of GP inhibition is not known \[[@pntd.0006349.ref098]\].

EBOV infection causes significant impairment of the endothelial barrier function. GP repression of ERK2 activity reduces integrin expression and cell adherence; however, GP also induces endothelial cell activation, further decreasing endothelial barrier functions \[[@pntd.0006349.ref099]\]. During EBOV infection of endothelial cells, cell adhesion molecules (CAM) ICAM-1 and VCAM-1 were found to be transcriptionally upregulated, with increased cell surface expression of CAMs. The activity occurs with cellular GP expression as well as following the transfer of GP-containing VLPs; viral replication does not appear to be required. Endothelial activation was not observed in the absence of GP, nor with the GP transcriptional variant sGP or the GP cleavage product Δ-peptide \[[@pntd.0006349.ref099]\]. GP-induced endothelial cell activation may facilitate decreased barrier function, whilst the up-regulation of CAMs may facilitate adhesion and subsequent infection of immune cells, such as macrophages. A model was proposed whereby activated endothelial cells result in increased leukocyte recruitment, resulting in thrombomodulin release, resulting in an activated, leukocyte-rich endothelium in a procoagulant state \[[@pntd.0006349.ref100]\]. Whether this is an unintended consequence of GP or has a role in increased viral spread and infectivity is yet to be investigated.

EBOV GP has also been implicated in modulation of the host immune system. GP on the cell plasma membrane has been shown to be cleaved by TNF-α-converting enzyme (TACE), resulting in the release of a soluble cleaved product called shed GP that is missing the transmembrane domain \[[@pntd.0006349.ref101]\]. Shed GP was seen to activate uninfected macrophages and dendritic cells, resulting in the production of multiple pro- and anti-inflammatory cytokines, including TNF-α, with subsequent effects on vascular permeability \[[@pntd.0006349.ref102]\]. It is thought that shed GP activates macrophages by binding to and activating toll-like receptor 4 (TLR4) in a manner requiring GP glycosylation. Recently it was also shown that full-length GP on VLPs can also trigger the activation of TLR4 in macrophages, resulting in a similar activation phenotype \[[@pntd.0006349.ref103]\]. In contrast, GP binding to TLR4 on T lymphocytes directly triggers cell death through an up-regulation of caspase 9, even in the absence of infection \[[@pntd.0006349.ref104]\]. In dendritic cells, GP was found to interact with the liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin), a C-type lectin that contains two amino acids, residues N256 and N274, that bind GP in a Ca^2+^-dependant manner, triggering the activation of spleen tyrosine kinase (Syk) signalling and the production of inflammatory cytokines TNF-α and interleukin-6 (IL-6) \[[@pntd.0006349.ref105]\]. As shed GP retains most of the structure of full-length GP, this soluble molecule is capable of binding to and neutralising circulating anti-GP antibodies, facilitating viral immune evasion \[[@pntd.0006349.ref101]\].

Similarly, sGP has been implicated in evading the immune system via antigenic subversion \[[@pntd.0006349.ref106]\]. It was found that boosting GP-immunised mice with sGP biased B-cell response towards epitopes that were shared between sGP and GP, reducing GP-specific antibody production and possibly impeding the immune-mediated clearance of EBOV infection. The structure of sGP in complex with antibodies was recently solved and highlights differences in antibody reactivity between GP and sGP \[[@pntd.0006349.ref107]\]. Whilst GP is trimeric, sGP oligomerises into a parallel homodimer. Cross-reactive c13C6 antibody epitopes are presented similarly on GP and sGP, though the authors report that one c13C6 antibody binds to one GP trimer, whereas multiple different immune-complexes were formed with sGP, ranging from rectangular complexes with a 2:2 ratio of c13C6 antibody to sGP dimer up to pentagonal 5:5 antibody:sGP complexes \[[@pntd.0006349.ref107]\]. This further supports the hypothesis that sGP enhances viral immune evasion by biasing the antibody response towards sGP binding.

Whilst the multitude of GP secondary effects have a significant impact on EBOV infection, pathogenesis, and immune evasion, GP remains the immunodominant protein on the EBOV virion, and vaccination with the GP protein on pseudotyped viruses, recombinant vesicular stomatitis virus with *Zaire ebolavirus* GP (rVSV-ZEBOV), has been highly effective in preventing EVD \[[@pntd.0006349.ref007]\].

NP and L {#sec007}
========

NP has a distinct function in the replication cycle as it is a key component of the viral ribonucleoprotein complex and has critical roles in protecting vRNA from degradation and in mediating genome encapsidation during virus assembly \[[@pntd.0006349.ref010]\]. At present, all research has focused on these primary activities of NP, and any secondary roles remain to be determined \[[@pntd.0006349.ref018],[@pntd.0006349.ref025],[@pntd.0006349.ref040]\]. Similarly, the RNA-dependent L-polymerase is an essential component of the RdRp complex and required for viral genome transcription and replication \[[@pntd.0006349.ref010]\]. It has been observed that L can also edit mRNA, as seen with the GP gene, where L-editing results in the production of the GP transcript instead of sGP \[[@pntd.0006349.ref108]\]. L-editing may also regulate the different expression levels of GP, sGP and ssGP. During serial passage in tissue culture cells, L was found to add a single uridine (U) residue to a site consisting of 7 Us in the GP gene, changing the expression ratio of GP:sGP to 80:20. A single passage in guinea pigs caused reversion of the genome back to 7 Us and changed the GP:sGP expression ratio back to 20:80, which may facilitate immune evasion during in vivo replication \[[@pntd.0006349.ref109]\]. In contrast, during viral replication in the human hepatocarcinoma cell line (Huh7), a 9U variant was seen that retained the high level expression of sGP but had enhanced expression of ssGP \[[@pntd.0006349.ref071]\]. It is speculated that these rapid alterations in the GP gene may act as a regulatory mechanism, enabling efficient virus replication in different host environments. At present, no other roles for the L protein have been postulated.

Conclusion {#sec008}
==========

For many years now, the fundamental principles of ebolavirus replication have been known, with each viral protein playing a specific role: L and VP30 form the RdRp and mediate viral genome transcription and replication, NP packages the vRNA genome and forms the nucleocapsid, VP40 mediates virion assembly and budding, GP mediates virion attachment to and fusion with the host cell, and VP24 and VP35 enable evasion of the host immune system. However, in recent years, our understanding of ebolavirus replication and pathogenesis has significantly increased, and we now know that each viral protein plays a multitude of overlapping roles during virus replication.

VP24 and VP35 were thought to primarily mediate immune evasion but have now been seen to function in viral replication and in the formation of the nucleocapsid. Similarly, many of the viral proteins that were thought to play functional roles in replication (i.e., VP30, VP40, GP) have now been discovered to have significant roles in immune evasion. This broadens our understanding of the ways in which ebolaviruses can evade and subvert the host immune system. Of particular interest is the observation that VP30, VP35, and VP40 all appear to supress the host RNA silencing system, though the relevance of this to viral replication is not yet clear ([Fig 3](#pntd.0006349.g003){ref-type="fig"}). In addition, many ebolavirus proteins are seen to interact with immune cells, causing cell activation and/or cell death and facilitating both viral replication and spread (e.g., by recruiting monocytes to infected cells or by increasing vascular leakage) as well as enabling immune evasion (e.g., antibody neutralisation by sGP and by cleaved GP), roles that were previously solely attributed to VP24 and VP35.

Since Project BioShield was initiated in 2004, there has been a substantial increase in our understanding of ebolavirus replication and pathogenesis. Several vaccines and antiviral therapeutics have been developed and were used during the 2014--2016 West Africa Ebola virus outbreak. However, the outbreak was difficult to contain and highlighted the fact that there are many significant aspects of EBOV that we do not yet understand (e.g., EBOV persistence in immunologically privileged tissue) and that there is a pressing need for continued research to better understand and combat this deadly pathogen.

Key learning points {#sec009}
-------------------

-   Recent research has uncovered new functions of many ebolavirus proteins that appear to be unrelated to the protein's primary function during virus replication.

-   Viral structural proteins, such as VP40 and GP, have been found to cause cell death in a wide range of cell types, including bystander T lymphocytes.

-   Viral immune modulating proteins, such as VP24 and VP35, now have significantly expanded functions during virus replication, including the regulation of viral particle formation.
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